Renal Replacement Therapy Childrens Healthcare of Atlanta.

Renal Replacement Therapy

Children’s Healthcare of Atlanta

Renal Replacement Therapy

• What is it?– The medical approach to providing the

electrolyte balance, fluid balance, and toxin removal functions of the kidney.

• How does it work?– Uses concentration and pressure gradients to

remove solutes (K, Urea, etc…) and solvents (water) from the human body.

Where did it come from?

• In Germany during 1979, Dr. Kramer inadvertently cannulated the femoral artery of a patient which led to a spontaneous experiment with CAVH (continuous arteriovenous hemofiltration)

– The patient's cardiac function alone is capable of driving the system

– Large volumes of ultrafiltrate were produced through the highly permeable hemofilter

– Continuous arteriovenous hemofiltration could provide complete renal replacement therapy in an anuric adult

History of Pediatric Hemofiltration

• USA, 1985: Dr. Liebermann used SCUF (slow continuous ultrafiltration) to successfully support an anuric neonate with fluid overload

• Italy, 1986: Dr. Ronco described the successful use of CAVH in four neonates

• USA, 1987: Dr. Leone described CAVH in older children

• 1993: A general acceptance of pump-driven CVVH was seen as less problematic than CAVH

•In 1984, Dr. Claudio Ronco, treated this child with CAVH in Vicenza, Italy. This is the first patient purposely treated with CAVH in the world. The patient survived.

Mechanisms of Action: Convection• Hydrostatic pressure pushes solvent across a semi-permeable membrane

• Solute is carried along with solvent by a process known as “solvent drag”

• Membrane pore size limits molecular transfer

• Efficient at removal of larger molecules compared with diffusion

Pressure

Na

H2O H2O + Na

• Solvent moves up a concentration gradient

• Solute diffuses down an concentration gradient– Solute movement occurs via Brownian motion

• The smaller the molecule (e.g. urea) the greater the kinetic energy

• The larger the concentration gradient the more drive for movement

• Therefore, smaller molecules with greater concentration gradients move more quickly across membrane

Mechanisms of Action: Diffusion

Osmolarity

H2O H2O

Osmolarity

Urea Urea

Uremia

Semi-permeable Membranes

– Urea

– Creatinine

– Uric acid

– Sodium

– Potassium

– Ionized calcium

– Phosphate

– Almost all drugs not bound to plasma proteins

•Allow easy transfer of solutes less than 100 Daltons

– Bicarbonate

– Interleukin-1

– Interleukin-6

– Endotoxin

– Vancomycin

– Heparin

– Pesticides

– Ammonia

•Are impermeable to albumin and other solutes of greater than 50,000 Daltons


• Sieving Coefficient– Defines amount (clearance) of molecule that

crosses semi-permeable membrane

• Sieving Coefficient is “1” for molecules that easily pass through the membrane and “0” for those that do not


• Continuous hemofiltration

membranes consist of

relatively straight channels

of ever-increasing diameter

that offer little resistance to

fluid flow

• Intermittent hemodialysis

membranes contain long,

tortuous inter-connecting

channels that result in high

resistance to fluid flow

How is it done?

• Peritoneal Dialysis• Hemodialysis• Hemofiltration• The choice of which modality to use depends on

– Patient’s clinical status

– Resources available

Peritoneal Dialysis

• Fluid placed into peritoneal cavity by catheter

• Glucose provides solvent gradient for fluid removal from body

• Can vary concentration of electrolytes to control hyperkalemia

• Can remove urea and metabolic products

• Can be intermittent or continuously cycled

Peritoneal dialysis

• Simple to set up & perform

• Easy to use in infants

• Hemodynamic stability

• No anti-coagulation

• Bedside peritoneal access

• Treat severe hypothermia or hyperthermia

• Unreliable ultrafiltration

• Slow fluid & solute removal

• Drainage failure & leakage

• Catheter obstruction

• Respiratory compromise

• Hyperglycemia

• Peritonitis

• Not good for hyperammonemia or intoxication with dialyzable poisons

Advantages Disadvantages

Intermittent Hemodialysis

• Maximum solute clearance of 3 modalities

• Best therapy for severe hyperkalemia

• Limited anti-coagulation time

• Bedside vascular access can be used

• Hemodynamic instability

• Hypoxemia

• Rapid fluid and electrolyte shifts

• Complex equipment

• Specialized personnel

• Difficult in small infants


Continuous Hemofiltration

• Easy to use in PICU

• Rapid electrolyte correction

• Excellent solute clearances

• Rapid acid/base correction

• Controllable fluid balance

• Tolerated by unstable patients

• Early use of TPN

• Bedside vascular access routine

• Systemic anticoagulation (except citrate)

• Frequent filter clotting

• Vascular access in infants


SCUF:Slow Continuous UltrafiltrationBlood is pushed through a hemofilter

Pressure generated within filter pushes solvent (serum) through semi-permeable membrane (convection)

Solutes are carried through membrane by a process known as “solvent drag”

Urea Creatinine

K Na H2O

Blood

Ultrafiltrate

Pressure

Control rate of fluid removal

SCUF:Slow Continuous Ultrafiltration

• Pros– Filters blood effectively

– Control fluid balance by regulating transmembrane pressures

– No replacement fluid therefore less pharmacy cost

• Cons– No replacement fluid

given so electrolyte abnormalities can occur

– Low ultrafiltration rates that keep electrolytes balanced do not remove urea effectively

CVVHBlood is pushed through a hemofilter

Pressure within filter (convection)

Solvent Drag

Urea Creatinine

K Na H2O

Ultrafiltrate

Replacement Fluid

BloodPressure

Replacement fluid given back to patient

Continuous Venovenous Hemofiltration

• Filtration occurs by convection

• Mimics physiology of the mammalian kidney

– Provides better removal of middle molecules (500-5000

Daltons) thought to be responsible clinical state of uremia

• Ultrafiltrate is replaced by a sterile solution

(replacement solution)

• Patient fluid loss (or gain) results from the difference

between ultrafiltration and replacement rates

CVVHDBlood is pushed through a hemofilter

Urea Creatinine

K Na H2O

Dialysate

Blood

Dialysis Fluid

Dialysis fluid flows counter-

current to blood flow

Water and Solutes move across

concentration gradients

(diffusion)

Continuous Venovenous Hemodialysis

• Diffusion (predominantly)– Some convection occurs due to transmembrane

pressure created by roller-head pump

• Dialysate flow rate is slower than BFR and is the limiting factor to solute removal– Therefore, solute removal is directly

proportional to dialysate flow rate

CVVHDF

Urea Creatinine

K Na H2O

Replacement Fluid

Blood

Dialysis Fluid Dialysate

Pressure

Blood is pushed through a hemofilter

Dialysis fluid flows counter- current to blood flow

Water and Solutes move across

concentration gradients

(diffusion)

Pressure within filter (convection)

Solvent Drag

Replacement fluid given back to patient

Continuous Venovenous Hemodialysis with Ultrafiltration

• Pros– Can provide both

ultrafiltration (removal of medium size molecules) and dialysis (removal of small molecules)

– Can remove toxins

• Cons– Toxin removal is slow

– Overly complicated to set-up for small clinical benefits

Is there a “Best” Method?

• The greatest difference between modalities is most likely related to the membrane utilized and their specific characteristics.

• There are no data available assessing patient outcomes using diffusive (CVVHD) and convective (CVVH) therapies

Indications for Renal Replacement Therapy

• Intractable acidosis• Fluid overload or

pulmonary edema• BUN > 150 mg/dL• Symptomatic uremia

(encephalopathy, pericarditis)

• Hyperkalemia (serum K > 7 mEq/L)

• Hyperammonemia• Ultrafiltration for

nutritional support or excessive transfusions

• Exogenous toxin removal• Hyponatremia or

hypernatremia

Adapted From Rogers’ Textbook of Pediatric Intensive Care, Table 38.7

Indicators of Circuit Function

Filtration Fraction

• The degree of blood dehydration can be estimated by

determining the filtration fraction (FF)

– The fraction of plasma water removed by ultrafiltration

FF(%) = (UFR x 100) / QP

where QP is the filter plasma flow rate in ml/min

QP = BFR* x (1-Hct)

*BFR: blood flow rate

Ultrafiltrate Rate

FF(%) = (UFR x 100) / QP

QP = BFR x (1-Hct) • For example...

– When BFR = 100 ml/min & Hct = 0.30 (i.e. 30%), the QP = 70 ml/min

– A filtration fraction > 30% promotes filter clotting

– In this example, when the maximum allowable FF is set at 30%, a BFR of 100 ml/min yields a UFR = 21 ml/min

QP: the filter plasma flow rate in ml/min

Blood Flow Rate & Clearance

• A child with body surface area = 1.0 m2, BFR = 100 ml/min and FF = 30%– Small solute clearance is 36.3 ml/min/1.73 m2

(About one third of normal renal small solute clearance)

• Target CVVH clearance of at least 15 ml/min/1.73 m2

– For small children, BFR > 100 ml/min is usually unnecessary

– High BFR may contribute to increased hemolysis within the CVVH circuit

Pediatric CRRT Vascular Access:Performance = Blood Flow!!!

• Minimum 30 to 50 ml/min to minimize access and filter clotting

• Maximum rate of 400 ml/min/1.73m2 or– 10-12 ml/kg/min in neonates and infants

– 4-6 ml/kg/min in children

– 2-4 ml/kg/min in adolescents

Urea Clearance

• Urea clearance (C urea) in hemofiltration, adjusted for the patient's body surface area (BSA), can be calculated as follows:

C urea = UF [urea] x UFR x 1.73

BUN pt’s BSA

In CVVH, ultrafiltrate urea concentration and BUN are the same, canceling out of the equation, which becomes:

C urea = UFR x 1.73

pt’s BSA

C urea: (ml/min/1.73 m2 BSA)

Urea Clearance

• When target urea clearance (C urea) is set at 15 ml/min/1.73 m2, the equation can be solved for UFR

15 = UFR x 1.73 / pt’s BSA

UFR = 15 / 1.73 = 8.7 ml/min• Thus, in a child with body surface area = 1.0 m2, a C

urea of about 15 ml/min/1.73 m2 is obtained when UFR = 8.7 ml/min or 520 ml/hr.

• This same clearance can be achieved in the 1.73 m2 adolescent with a UFR = 900 ml/hr.

Solute Molecular Weight and Clearance

Solute (MW) Convective Coefficient Diffusion Coefficient

Urea (60) 1.01 ± 0.05 1.01 ± 0.07

Creatinine (113) 1.00 ± 0.09 1.01 ± 0.06

Uric Acid (168) 1.01 ± 0.04 0.97 ± 0.04

Vancomycin (1448) 0.84 ± 0.10 0.74 ± 0.04

Cytokines (large) adsorbed minimal clearance

•Drug therapy can be adjusted by using frequent blood level determinations or by using tables that provide dosage adjustments in patients with altered renal function

Fluid Balance

• Precise fluid balance is one of the most useful features of CVVH

• Each hour, the volume of filtration replacement fluid (FRF) is adjusted to yield the desired fluid balance.

-FRFto be givenin next hour

= total fluid outin the previous

hour

total fluid inexcluding

FRF

- desiredfluid balance

Replacement Fluids

• Ultrafiltrate can be replaced with a combination of:

– Custom physiologic solutions

– Ringer’s lactate

– Total parenteral nutrition solutions

• In patients with fluid overload, a portion of the

ultrafiltrate volume is simply not replaced, resulting in

predictable and controllable negative fluid balance.

Physiologic Replacement Fluid

• Na 135-145 mEq/L

• K 2.5-4.5 mEq/L

• HCO3 25-35 mEq/l

• Cl Balance

• Ca 2.5 mEq/L

• Mg 1.5 mEq/L

• Glucose 100 mg/dL

Anticoagulation

• To prevent clotting within the CVVH circuit, active anti-coagulation is often needed– Heparin– Citrate– Local vs. systemic

Mechanisms of Filter Thrombosis

CONTACT PHASECONTACT PHASEXII activationXII activation

XI IXXI IX

TISSUE FACTOR TISSUE FACTOR TF:VIIaTF:VIIa

THROMBINTHROMBIN

fibrinogenfibrinogen

prothrombinprothrombin

XaXaVa Va VIIIa VIIIa CaCa++++ plateletsplatelets

CLOTCLOT

monocytesmonocytes / / platelets / platelets / macrophages macrophages

FIBRINOLYSIS ACTIVATIONFIBRINOLYSIS ACTIVATION

FIBRINOLYSIS INHIBITIONFIBRINOLYSIS INHIBITION

NATURAL NATURAL ANTICOAGULANTSANTICOAGULANTS(APC, ATIII)(APC, ATIII)

XX

Phospholipid Phospholipid surfacesurface

CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++

Sites of Action of Heparin

CONTACT PHASECONTACT PHASEXII activationXII activation

XI IXXI IX


THROMBINTHROMBIN



XaXa

Va Va VIIIa VIIIa CaCa++++ plateletsplatelets

CLOTCLOT

monocytes monocytes platelets platelets macrophages macrophages




XX


CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++

UF HEPARINUF HEPARIN

ATIIIATIII

Heparin - Problems

• Bleeding

• Unable to inhibit thrombin bound to clot

• Unable to inhibit Xa bound to clot

• Ongoing thrombin generation

• Direct activation of platelets

• Thrombocytopenia

• Extrinsic pathway unaffected

No Heparin Systemically Heparinized

NO surface - no heparin NO surface - heparinized

Compliments of Dr. Gail Annich, University of MichiganCompliments of Dr. Gail Annich, University of Michigan

Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.

Unfractionated Heparin

Sites of Action of CitrateCONTACT PHASECONTACT PHASE

XII activationXII activationXI IXXI IX


THROMBINTHROMBIN



XaXa

Va Va VIIIa VIIIa CaCa++++ plateletsplatelets

CLOTCLOT

monocytesmonocytes / / platelets / platelets / macrophages macrophages




XX


CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++CaCa++

++

CITRATECITRATE

Anticoagulation: Citrate

• Citrate regional anticoagulation of the CVVH circuit may be employed when systemic (i.e., patient) anticoagulation is contraindicated for any reason (usually, when a severe coagulopathy pre-exists).

• CVVH-D helps prevent inducing hypernatremia with the trisodium citrate solution

Anticoagulation: citrate

• Citrate regional anticoagulation of the CVVH circuit:– 4% trisodium citrate ‘pre-filter’

– Replacement fluid: normal saline

– Calcium infusion: 8% CaCl in NS through a distal site

• Ionized calcium in the circuit will drop to < 0.3, while the systemic calcium concentration is maintained by the infusion.

Citrate

Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.

Citrate: Problems

• Metabolic alkalosis

– metabolized in liver / skeletal

muscle / other tissues

• Electrolyte disorders

– Hypernatremia

– Hypocalcemia

– Hypomagnesemia

• May not be able to use in

– Congenital metabolic diseases

– Severe liver disease / hepatic

failure

• May be issue with massive

blood transfusions

Experimental: High Flow

• High-volume CVVH might…– Improve hemodynamics– Increase organ blood flow– Decrease blood lactate and nitrite/nitrate

concentrations.

Ronco et al. Lancet 2000; 351: 26-30

1 4 6 U F ra te 20 m l/kg /h rsu rv iva l sig n if ica n tly lo w er

in th is g ro up com pa redto th e o the rs

1 3 9 U F ra te 35 m l/kg /h rp = 0 .00 07

1 4 0 U F ra te 45 m l/kg /h rp = 0 .00 13

4 2 5 pa tien tsE n d p o in t = su rv iva l 1 5 d a ys a fte r D /C H F

35 mL/kg/hr ~ 40 cc/min/1.73 m2

Ronco et al. Lancet 2000; 351: 26-30

• Conclusions:– Minimum UF rates should reach at least 35

ml/kg/hr (40 mL/min/1.73 m2)– Survivors in all their groups had lower BUNs

than non-survivors prior to commencement of hemofiltration

Experimental: septic shock• Zero balance ultrafiltration (ZBUF) performed

– 3L ultrafiltrate/h for 150 min then 6 L/h for an additional 150 min. UF @

6 L/min no UFmean art. BP (mmHg) 77 ± 19 40 ± 15 p < .05

cardiac index(mL/min.kg)

0.17 ± .04 0.06 ± .04 p < .05

stroke index (mL/kg) 1.0 ± 0.4 0.4 ± 0.3 p < .05

LV strokework index(g/m.kg)

1.0 ± 0.6 0.2 ± 0.2 p < .05

hepatic blood flow(% baseline)

+226 ± 68 +70 ± 34

Rogers et al: Effects of CVVH on regional blood flow and nitric oxide production in

canine endotoxic shock.

What are the targets?

• Most known mediators are water soluble• Possible contenders

– 500-60,000D (“middle molecules”)• cytokines

• anti/pro-coagulants

– Other molecules • complement

• phospholipase A-2 dependent products

• Likely many unknown contenders

Unknowns of Hemofiltration for Sepsis

• Interaction of immune system with foreign surface of the circuit?– Complement activation

– Bradykinin generation

– Leukocyte adhesion

• Clearance of anti-inflammatory mediators?• Clearance of unknown good mediators?• What do plasma levels of mediators really mean?• Is animal sepsis clinically applicable to human sepsis?

Clinical Applications in Pediatric ARF: Disease and Survival

Diagnosis N Survival Diagnosis N %Survival

BMT 26 42% HUS 16 94%

TLS/Malig 17 58% ATN 46 67%

CHD 47 39% Liver Tx 22 17%

Heart Tx 13 67% Sepsis 39 33%

Bunchman TE et al: Ped Neph 16:1067-1071, 2001

Clinical Applications in Pediatric ARF: Disease and Survival

• Patient survival on pressors (35%) lower survival than without pressors (89%) (p<0.01)

• Lower survival seen in CRRT than in patients who received HD for all disease states

Bunchman TE et al: Ped Neph 16:1067-1071, 2001

Pediatric CRRT in the PICU

• 22 pt (12 male/10 female) received 23 courses (3028 hrs) of CVVH (n=10) or CVVHD (n=12) over study period.

• Overall survival was 41% (9/22).

• Survival in septic patients was 45% (5/11).

• PRISM scores at ICU admission and CVVH initiation were 13.5 +/- 5.7 and 15.7 +/- 9.0, respectively (p=NS).

• Conditions leading to CVVH (D)– Sepsis (11)

– Cardiogenic shock (4)

– Hypovolemic ATN (2)

– End Stage Heart Disease (2)

– Hepatic necrosis, viral pneumonia, bowel obstruction and End-Stage Lung Disease (1 each)

Goldstein SL et al: Pediatrics 2001 Jun;107(6):1309-12

Percent Fluid Overload Calculation

% FO at CVVH initiation =[ Fluid In - Fluid OutICU Admit Weight ] * 100%


Renal Replacement Therapy in the PICU Pediatric Literature

• Lesser % FO at CVVH (D) initiation was associated with improved outcome (p=0.03)

• Lesser % FO at CVVH (D) initiation was also associated with improved outcome when sample was adjusted for severity of illness (p=0.03; multiple regression analysis)

Mean+SEMean-SE

Mean

OUTCOME

%F

O a

t CV

VH

Initi

atio

n

0

5

10

15

20

25

30

35

40

45

Death Survival

p = 0.03


PRISM at CRRT Initiation and Outcome

±Std. Dev.

±Std. Err.

Mean

OUTCOME

PR

ISM

AT

CR

RT

In

itia

tion

2

6

10

14

18

22

26

30

Death Survival

P < 0.0005

Fluid Overload and Outcome: Renal Failure Only

±Std. Dev.

±Std. Err.

Mean

OUTCOME

Pe

rce

nt

Flu

id O

verl

oa

d a

t C

RR

T I

niti

atio

n

-5

0

5

10

15

20

25

30

35

40

Death Survival

P < 0.05

Final Thoughts on Hemofiltration

• Medical Therapy that can perform the functions of the kidney and provide precise electrolyte and fluid balance

• Unknown which method (CVVH vs. CVVHD vs. CVVHDF) is best

• Many applications in the PICU

• No perfect method of coagulation

• High flow replacement fluids may be beneficial in sepsis

• Earlier use in fluid overloaded patients with lower PRISM scores may improve mortality

These slides created from presentations by...

Joseph DiCarlo, MDStanford University

Steven Alexander, MDStanford University

Catherine Headrick, RNChildren’s Medical Center Dallas

Patrick D. Brophy, MDUniversity of Michigan

Peter Skippen, MDBritish Columbia Children’s Hospital

Stuart L. Goldstein, MDBaylor College of Medicine

Timothy E. Bunchman, MDUniversity of Alabama

Renal Replacement Therapy Childrens Healthcare of Atlanta.

Documents

Transcript of Renal Replacement Therapy Childrens Healthcare of Atlanta.